SOHM (OTC: SHMN), a cutting-edge biopharmaceutical company focused on gene editing technologies, today announced its collaboration with Coastar Therapeutics, San Diego, California, a leading biotechnology company specializing in innovative drug delivery systems. The partnership aims to advance the field of genome editing using Coastar’s red blood cell membrane derived carriers and SOHM’s ABBIE (A Binding Based Integrase Enzyme) genome editing technology. “Coastar’s novel carriers offer a unique and promising approach to enhance the delivery of our ABBIE protein complexes,” said Dr. David Aguilar, COO of SOHM. “This collaboration aligns perfectly with our mission to develop innovative gene editing technologies that can be applied in a wide range of therapeutic applications. We are excited about the potential impact this collaboration can have on the field of genome editing.”
To view the full press release, visit https://ibn.fm/SZwfh
About SOHM, Inc.
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. To learn more about the company, visit www.SOHM.com.
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN